RESUMEN
BACKGROUND: In this paper, we review lessons learned about Universal Health Coverage (UHC) in middle-income countries, with specific reference to achievements and challenges observed during recent years in four middle-income to upper-middle-income countries - Mexico, Turkey, The Republic of Korea and Ukraine. Three of these countries - Mexico, the Republic of Korea, Turkey are members of the Organization for Economic Cooperation and Development (OECD). Ukraine has aspired to join Western institutions like the OECD since its independence in 1991. METHODS: The research included a combination of cross-sectional and longitudinal reviews of both statistical and contextual data, available from both published sources and available "grey literature" reports. RESULTS: Based on the research, we conclude the following. First, reaching UHC is achievable in middle-income and upper-middle-income countries. It is not an unattainable goal reserved for upper income countries. Second, successes and failures are evident both in the case of countries that pursue a contributory health insurance path to UHC and those that pursue a core government funding path. Third, the devil is often in the detail. De jure constitutional guarantees and national health legislation are often a necessary but do not constitute a guaranteed path to success without accompanying institutional measure to secure sustainability (political and economic) and supply and demand constraints in service provision and consumer/patient behavior. De facto, in most countries expansion in health insurance coverage does not happen "with the stroke of a pen" but require years of commitment and efforts to change the supply and demand after critical legislation has been enacted. Fourth, two major approaches dominate: incremental and "big bang" health system reforms. CONCLUSIONS: We caution against the pitfalls of over-attribution from drawing too strong conclusion from individual longitudinal country experiences ("over-determinism") and over-generalization from broad sweeping cross-sectional statistical analysis ("reductionism"). Every country is different and needs to find its own path towards UHC considering their contextual specificities, learning from the achievements and failures of others, but not try to copy their experiences.
Asunto(s)
Países en Desarrollo , Atención de Salud Universal , Estudios Transversales , Humanos , Renta , Cobertura Universal del Seguro de SaludAsunto(s)
Salud Ambiental/normas , Contaminación Ambiental/efectos adversos , Salud Global/normas , Adolescente , Adulto , Distribución por Edad , Anciano , Contaminantes Atmosféricos/efectos adversos , Niño , Preescolar , Enfermedad Crónica/epidemiología , Enfermedad Crónica/prevención & control , Conservación de los Recursos Naturales , Costo de Enfermedad , Salud Ambiental/economía , Salud Ambiental/legislación & jurisprudencia , Contaminación Ambiental/prevención & control , Femenino , Salud Global/estadística & datos numéricos , Política de Salud , Disparidades en el Estado de Salud , Humanos , Lactante , Recién Nacido , Cooperación Internacional , Masculino , Persona de Mediana Edad , Mortalidad Prematura , Enfermedades no Transmisibles/epidemiología , Salud Laboral/normas , Pobreza , Características de la Residencia , Contaminantes del Suelo/efectos adversos , Contaminantes del Agua/efectos adversos , Organización Mundial de la Salud , Adulto JovenRESUMEN
BACKGROUND: The research done for this paper is part of the background analysis undertaken to support the work of the Global Commission on Pollution, Health and Development, an initiative of The Lancet, the Global Alliance on Health and Pollution, and the Icahn School of Medicine at Mount Sinai. The paper expands on areas where the current literature has gaps in knowledge related to the health care cost of pollution. OBJECTIVES: This study aims to generate an initial estimate of total tangible health care expenditure attributable to man-made pollution affecting air, soil and water. METHODS: We use two methodologies to establish an upper and lower bounds for pollution related health expenditure. Key data points in both models include (a) burden-of-disease (BoD) at the national level in different countries attributable to pollution; and (b) the total cost of health care at the national level in different countries using standard national health accounts expenditure data. FINDINGS: Depending on which determinist model we apply, annual expenditures range from US$630 billion (upper bound) to US$240 billion (lower bound) or approximately three to nine percent of global spending on health care in 2013 (the reference year for the analysis). Although only 14 percent of global total for pollution related health care spending is in lower- and middle-income countries (LMICs) in our primary (lower bound) model, the relative share of spending for pollution related illness is substantial, especially in very low-income countries. Cancer, chronic respiratory and cardio/cerebrovascular illnesses account for the largest health care spending items linked to pollution even in LMICs. CONCLUSIONS: These conditions have historically received less attention by national governments, international public health organizations and development/financial agencies than infectious disease and maternal/child health sectors. Other studies posit that intangible costs associated with environmental pollution include lower productivity and reduced income - components which our models do not attempt to capture. The financial and health impacts are substantial even when we exclude intangible costs, yet it is likely that in many LMICs poor households simply forgo medical treatment and lose household income as a result of man-made environmental degradation. RECOMMENDATIONS: When evaluating the value of public health or environmental programs which prevent or limit pollution-related illness, policy makers should consider the health benefits, the tangible cost offsets (estimated in our models) and the opportunity costs.
Asunto(s)
Atención a la Salud/economía , Contaminantes Ambientales/efectos adversos , Contaminantes Ambientales/economía , Costos de la Atención en Salud , Gastos en Salud/estadística & datos numéricos , HumanosRESUMEN
From June 27th to July 1st 2016, the International Hospital Federation (IHF) and Health Investment & Financing hosted a Hospital Executive Study Tour in New York City, NY, USA. The objective of the Hospital Executive Study Tour was to enable participant to learn how the US hospital sector addresses some of the key challenges and solutions in transforming the way hospital care is delivered in the 21st Century. The New York Study Tour was part of a series of premier events offered by the IHF. This Study Tour was a collaborative effort among regional members and partner organizations in hosting various events to allow an exchange of ideas, knowledge, experiences and best practices in the delivery of healthcare services, and in the leadership and management of their organizations.